2 Information about rimegepant

Marketing authorisation indication

2.1 Rimegepant (Vydura, Pfizer) is indicated for the 'preventative treatment of episodic migraine in adults who have at least 4 migraine attacks per month'.

2.2 Rimegepant for acute treatment is recommended in NICE's technology appraisal guidance on rimegepant for treating migraine.

Dosage in the marketing authorisation

2.3 The dosage schedule is available in the summary of product characteristics for rimegepant.


2.4 The proposed price of rimegepant is £12.90 per 75 mg tablet (excluding VAT).

  • National Institute for Health and Care Excellence (NICE)